Literature DB >> 21465565

COMT Val(158) met genotype and striatal D(2/3) receptor binding in adults with 22q11 deletion syndrome.

Erik Boot1, Jan Booij, Janneke R Zinkstok, Frank Baas, Ann Swillen, Michael J Owen, Declan G Murphy, Kieran C Murphy, Don H Linszen, Thérèse A Van Amelsvoort.   

Abstract

Although catechol-O-methyltransferase (COMT) activity evidently affects dopamine function in prefrontal cortex, the contribution is assumed less significant in striatum. We studied whether a functional polymorphism in the COMT gene (Val(158) Met) influences striatal D(2/3) R binding ratios (D(2/3) R BP(ND) ) in 15 adults with 22q11 deletion syndrome and hemizygous for this gene, using single photon emission computed tomography and the selective D(2/3) radioligand [(123) I]IBZM. Met hemizygotes had significantly lower mean D(2/3) R BPND than Val hemizygotes. These preliminary data suggest that low COMT activity may affect dopamine levels in striatum in humans and this may have implications for understanding the contribution of COMT activity to psychiatric disorders.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465565     DOI: 10.1002/syn.20932

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  7 in total

Review 1.  Neurobiological perspective of 22q11.2 deletion syndrome.

Authors:  Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort
Journal:  Lancet Psychiatry       Date:  2019-08-05       Impact factor: 27.083

2.  PRODH rs450046 and proline x COMT Val¹⁵⁸ Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome.

Authors:  Mariken B de Koning; Esther D A van Duin; Erik Boot; Oswald J N Bloemen; Jaap A Bakker; Kathryn M Abel; Thérèse A M J van Amelsvoort
Journal:  Psychopharmacology (Berl)       Date:  2015-06-12       Impact factor: 4.530

Review 3.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

Review 4.  Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies.

Authors:  B S Gluskin; B J Mickey
Journal:  Transl Psychiatry       Date:  2016-03-01       Impact factor: 6.222

5.  Lower [18F]fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome: a positron emission tomography study.

Authors:  Esther D A van Duin; Jenny Ceccarini; Jan Booij; Zuzana Kasanova; Claudia Vingerhoets; Jytte van Huijstee; Alexander Heinzel; Siamak Mohammadkhani-Shali; Oliver Winz; Felix Mottaghy; Inez Myin-Germeys; Thérèse van Amelsvoort
Journal:  Psychol Med       Date:  2019-04-02       Impact factor: 7.723

6.  Neural correlates of reward processing in adults with 22q11 deletion syndrome.

Authors:  Esther D A van Duin; Liesbet Goossens; Dennis Hernaus; Fabiana da Silva Alves; Nicole Schmitz; Koen Schruers; Therese van Amelsvoort
Journal:  J Neurodev Disord       Date:  2016-07-15       Impact factor: 4.025

7.  Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 Polymorphisms and Treatment Resistance in Schizophrenia.

Authors:  Marina Sagud; Lucija Tudor; Suzana Uzun; Matea Nikolac Perkovic; Maja Zivkovic; Marcela Konjevod; Oliver Kozumplik; Bjanka Vuksan Cusa; Dubravka Svob Strac; Iva Rados; Ninoslav Mimica; Alma Mihaljevic Peles; Gordana Nedic Erjavec; Nela Pivac
Journal:  Front Pharmacol       Date:  2018-07-03       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.